CEO of Raygent Associates
Contributor's Links: Raygent

Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 35 years executive experience including Abbott and JNJ and has been involved three successful start-ups. Before starting Raygent and other companies he was also a ... more

ALL CONTRIBUTIONS

HH Biotech Bear Market: But Is It Time To Start Trading?
The Nasdaq is down 1.6% and the Russell 2000 is down 1.8%, killing hopes of a continued Post-Election rally. The biotech sector is for experienced traders only. Healthcare still looks good overall with the XLV down only 0.29% at $92.95.
Read
Biotech Bull Market Under Pressure: Now Flat To Down In 2018
Here are some positive and negative indicators to consider on the future direction of biotechnology stocks.
Read
Biotech Snapshot: Healthcare Sector Remains Strong
FBT down 0.75% at $151.78, IBB down 0.58% at $117.32, XBI down 0.64% at $96.08.
Read
Biopharma Portfolio 2018 YTD: Performance Summary
The best way to make money in biotechnology is to hold the best companies over the long-term.
Read
Biotech Snapshot During A Rally Day: No Summer Doldrums…
Biotech stocks were mixed trading closer to the flatline after the close last night, on light summer volume. Macro issues such as drug pricing, trade and the Fed remain a concern.
Read
Q2 Earnings Update: Bluebird Bio (BLUE) And Regeneron (REGN)
Regeneron Pharmaceuticals (REGN) soared 7% to $397 on earnings beat with adjusted EPS of $5.45. Bluebird Bio (BLUE) was up 0.79% to $156.60 despite losses and lagging revenue.
Read

Comments

Latest Comments
Regulatory News For Rare Disease Products - Hot Stocks: BLUE, ICPT, SRPT
3 years ago

Getting trial information and following them is the hard part as it takes too much time. Just sett up the stocks in a Yahoo portfolio and track daily. The WEB site of the Company usually lets you know if trial results are coming in and when.

In this article: BLUE, ICPT, SRPT
Biotech Buzz Is Broken
3 years ago

Here is the YTD for KITE down 4.7%:

www.google.com/finance

In this article: JUNO, KITE, GILD, REGN
2015 Biotech Stock Preview: Rhythms Of The “PermaBull”
4 years ago

prefer a fund like FBIOX but XBI will work when the market heats up

In this article: XLV, FBT, FBIOX, GILD
1 to 3 of 3 comments

STOCKS I FOLLOW

ABAX ABAXIS Inc.
ALXN Alexion Pharmaceuticals, Inc.
AMRI Albany Molecular Research, Inc.
CBST Cubist Pharmaceuticals Inc.
GPRO GoPro, Inc.
QDEL Quidel Corporation

TWEETS

PERSONAL BLOG

Latest Posts

Work Experience

CEO
Raygent Associates
January 1990 - Present (29 years 5 months)
Biotechnology Intelligence www.raygent.com

Education

Penn State University
BS
Biochemistry
Rutgers University
MBA
Business

Publications